Folate decorated lipid chitosan hybrid nanoparticles of 5-fluorouracil for enhanced anticancer efficacy against colon cancer

Int J Biol Macromol. 2022 Dec 1;222(Pt A):497-508. doi: 10.1016/j.ijbiomac.2022.09.196. Epub 2022 Sep 26.

Abstract

The study aimed to develop folate decorated lipid chitosan hybrid nanoparticles for targeted delivery of 5-fluorouracil in colon cancer by utilizing the overexpressed folate receptors on the surface of HT-29 and HCT 116 cancer cell lines. The developed formulations were prepared by the ionic gelation method with slight modifications. The developed formulations exhibited spherical morphology, smaller particle size (158 to 225 nm), zeta potential (32.24 to 35.95 mV), PDI (0.19 to 0.35), and high encapsulation efficiency (85.3 % to 94.2 %) with optimal physicochemical characteristics. The in vitro release showed a biphasic release pattern with an initial burst release followed by a sustained release for 48 h. Moreover, the in vitro cell line study revealed that FA-CLPN-2 exhibited an enhanced cellular uptake and greater cytotoxic effect in HT-29 and HCT 116 cell lines compared to non-targeted CLPN-2 and free drug solution due to the folate receptor facilitated endocytosis process. The in vivo toxicity study revealed the safety and biocompatibility of the developed formulations in biological systems. The stability study demonstrates the stability of the developed formulations. Overall, these results suggest that the folate decorated lipid chitosan hybrid nanoparticles could be used as a potential delivery system for tumor-targeted therapy with reduced side effects.

Keywords: 5-Fluorouracil; Chitosan; Colorectal cancer; Folic acid; Nanomedicine.

MeSH terms

  • Cell Line, Tumor
  • Chitosan*
  • Colonic Neoplasms* / drug therapy
  • Drug Carriers
  • Drug Delivery Systems / methods
  • Fluorouracil / pharmacology
  • Folic Acid
  • Humans
  • Lipids
  • Nanoparticles*
  • Particle Size

Substances

  • Chitosan
  • Folic Acid
  • Fluorouracil
  • Lipids
  • Drug Carriers